5 results on '"Tuddow Thaiwong"'
Search Results
2. Development of a 17-Plex of Penta- and Tetra-Nucleotide Microsatellites for DNA Profiling and Paternity Testing in Horses
- Author
-
Andrea M. Luttman, Misa Komine, Tuddow Thaiwong, Tyler Carpenter, Susan L. Ewart, Matti Kiupel, Ingeborg M. Langohr, and Patrick J. Venta
- Subjects
tetranucleotide short tandem repeat ,horse ,17-plex ,DNA profiling ,Friesian ,paternity testing ,Veterinary medicine ,SF600-1100 - Abstract
Tetranucleotide and pentanucleotide short tandem repeat (hereafter termed tetraSTR and pentaSTR) polymorphisms have properties that make them desirable for DNA profiling and paternity testing. However, certain species, such as the horse, have far fewer tetraSTRs than other species and for this reason dinucleotide STRs (diSTRs) have become the standard for DNA profiling in horses, despite being less desirable for technical reasons. During our testing of a series of candidate genes as potentially underlying a heritable condition characterized by megaesophagus in the Friesian horse breed, we found that good tetraSTRs do exist in horses but, as expected, at a much lower frequency than in other species, e.g., dogs and humans. Using a series of efficient methods developed in our laboratory for the production of multiplexed tetraSTRs in other species, we identified a set of tetra- and pentaSTRs that we developed into a 17-plex panel for the horse, plus a sex-identifying marker near the amelogenin gene. These markers were tested in 128 horses representing 16 breeds as well as crossbred horses, and we found that these markers have useful genetic variability. Average observed heterozygosities (Ho) ranged from 0.53 to 0.89 for the individual markers (0.66 average Ho for all markers), and 0.62-0.82 for expected heterozygosity (He) within breeds (0.72 average He for all markers). The probability of identity (PI) within breeds for which 10 or more samples were available was at least 1.1 x 10−11, and the PI among siblings (PIsib) was 1.5 x 10−5. Stutter was ≤ 11% (average stutter for all markers combined was 6.9%) compared to the more than 30% typically seen with diSTRs. We predict that it will be possible to develop accurate allelic ladders for this multiplex panel that will make cross-laboratory comparisons easier and will also improve DNA profiling accuracy. Although we were only able to exclude candidate genes for Friesian horse megaesophagus with no unexcluded genes that are possibly causative at this point in time, the study helped us to refine the methods used to develop better tetraSTR multiplexed panels for species such as the horse that have a low frequency of tetraSTRs.
- Published
- 2022
- Full Text
- View/download PDF
3. Expression of Carboxypeptidase A3 and Tryptase as Markers for Lymph Node Metastasis of Canine Cutaneous Mast Cell Tumors
- Author
-
Tuddow Thaiwong, Juliana V. Cirillo, Jane Heller, and Matti Kiupel
- Subjects
mast cell tumor ,tryptase ,carboxypeptidase A3 ,prognosis ,canine ,lymph node metastasis ,Veterinary medicine ,SF600-1100 - Abstract
Detection of metastatic mast cell tumors (MCTs) in lymph nodes is a critical factor for treatment, prognosis, and clinical management. Presence/absence of mast cells in the lymph nodes cannot be used as a sole parameter to determine metastasis due to the inability to differentiate neoplastic from non-neoplastic/inflammatory mast cells. While cytologic and histopathologic classifications for assessment of metastatic MCTs based on the numbers and distribution of mast cells have been developed, inconsistency between the clinical interpretation of these grading schemes and actual metastatic status occurs. The aim of this study is to identify a novel diagnostic tool to accurately predict overt metastatic mast cell tumors in lymph nodes. We investigated the possibility of using RT-qPCR to detect mRNA expression of mast cell-specific genes in lymph nodes with different stages of MCT metastatic classification. We are able to establish a highly sensitive and discriminating RT-qPCR measuring Carboxy peptidase A3 (CPA3) and tryptase mRNA expression and identify the cut-off values with high sensitivity and specificity for overt metastatic MCTs in lymph nodes. An area of future interest would be to expand our analysis of the extent to which cut-off values for these markers in correctly identifying disease status, as well as predicting clinical outcomes and survival times. This would offer valuable information regarding the practical applicability of this technique and may enable us to improve our standards of detection metastasis, including possibility of molecular analysis of cytologic specimens obtained from suspicious nodes subjected to surgical excision.
- Published
- 2022
- Full Text
- View/download PDF
4. SupplementalFigures 1-4, Tables from Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
- Author
-
Beverly A. Mock, Joseph R. Testa, Wendy Dubois, R. Mark Simpson, Maudeline Etienne, Snehal Gaikwad, Matti Kiupel, Tuddow Thaiwong, Jin-Qiu Chen, Aleksandra M. Michalowski, Alexander L. Kovalchuk, Ke Zhang, Benjamin J. Gamache, Nicholas Watson, Tyler J. Peat, Shuling Zhang, Jinfei Xu, John K. Simmons, and Joy M. Gary
- Abstract
Supplemental Figures S1-S4 + two supp. tables
- Published
- 2023
- Full Text
- View/download PDF
5. Identification of a HypomorphiciFANCG/iVariant in Bernese Mountain Dogs
- Author
-
Katheryn Meek, Ya-Ting Yang, Marilia Takada, Maciej Parys, Marlee Richter, Alexander I. Engleberg, Tuddow Thaiwong, Rachel L. Griffin, Peter Z. Schall, Alana J. Kramer, and Vilma Yuzbasiyan-Gurkan
- Subjects
Bernese mountain dog ,histiocytic sarcoma ,fanconi anemia ,cancer ,comparative genetics ,Histiocytic Sarcoma/genetics ,Fanconi Anemia Complementation Group G Protein/genetics ,Mice ,Dogs ,Fanconi Anemia ,Fanconi Anemia/genetics ,Mutation ,Genetics ,Humans ,Animals ,Histiocytic Sarcoma ,Cisplatin ,Fanconi Anemia Complementation Group G Protein ,Genetics (clinical) ,Alleles - Abstract
Bernese mountain dogs (BMDs), have an overall cancer incidence of 50%, half of which is comprised of an otherwise rare tumor, histiocytic sarcoma (HS). While recent studies have identified driver mutations in the MAPK pathway, identification of key predisposing genes has been elusive. Studies have identified several loci to be associated with predisposition to HS in BMDs, including near the MTAP/CDKN2A region, but no causative coding variant has been identified. Here we report the presence of a coding polymorphism in the gene encoding FANCG, near the MTAP/CDKN2A locus. This variant is in a conserved region of the protein and appears to be specific to BMDs. Canine fibroblasts derived from dogs homozygous for this variant are hypersensitive to cisplatin. We show this canine FANCG variant and a previously defined hypomorphic FANCG allele in humans impart similar defects in DNA repair. However, our data also indicate that this variant is neither necessary nor sufficient for the development of HS. Furthermore, BMDs homozygous for this FANCG allele display none of the characteristic phenotypes associated with Fanconi anemia (FA) such as anemia, short stature, infertility, or an earlier age of onset for HS. This is similar to findings in FA deficient mice, which do not develop overt FA without secondary genetic mutations that exacerbate the FA deficit. In sum, our data suggest that dogs with deficits in the FA pathway are, like mice, innately resistant to the development of FA.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.